Connect Biopharma Holdings Ltd
CNTBNasdaq
$2.38
↑ +1.9%Jul 17 close · end-of-day
Price
1Y↑ +19.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$134.6M
Enterprise Value
$88.5M
P/E
—
P/S
577.6
P/B
3.2
EV/EBITDA
—
PEG
—
FCF Yield
-42.8%
Dividend Yield
—
Revenue (TTM)
$233,000.00
Net Income (TTM)
-$64.6M
Free Cash Flow (TTM)
-$57.6M
Gross Margin
—
Operating Margin
-28426.6%
Net Margin
-27727.9%
ROE
-151.6%
ROIC
—
Debt / Equity
—
Net Cash
$46.0M
Return 1Y
—
Company profile
Connect Biopharma Holdings Limited focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes. The company was founded in 2012 and is headquartered in Taicang, China.
- CEO
- Zheng Wei
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 110
- Headquarters
- California
- Website
- connectbiopharm.com
Earnings
CNTB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$169,000.00—
Diluted EPS-$0.34↑ +78.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $0.00 | $26.0M | $64,000.00 |
| Gross profit | — | — | — |
| Operating income | -$69.1M | -$22.5M | -$58.1M |
| Net income | -$62.1M | -$15.6M | -$55.5M |
| Diluted EPS | -$1.13 | -$0.28 | -$1.00 |
| Operating cash flow | -$47.7M | -$23.6M | -$51.2M |
| Free cash flow | -$47.8M | -$24.4M | -$51.6M |
| Gross margin | — | — | — |
| Operating margin | — | -86.2% | -90740.6% |
| Net margin | — | -60.0% | -86687.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24.1M | $1.2M | — | $0.00 | $48,000.00 | $16,000.00 | $0.00 | $169,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $13.6M | -$13.8M | -$9.6M | -$11.4M | -$13.4M | -$17.7M | -$15.5M | -$19.6M |
| Net income | $14.8M | -$12.9M | -$8.9M | -$10.3M | -$12.9M | -$17.2M | -$15.1M | -$19.4M |
| Diluted EPS | $0.27 | -$0.23 | -$0.16 | -$0.19 | -$0.23 | -$0.31 | -$0.27 | -$0.34 |
| Operating cash flow | -$7.7M | -$13.0M | -$2.3M | -$10.0M | -$12.6M | -$17.4M | -$11.3M | -$16.0M |
| Free cash flow | -$8.0M | -$13.2M | -$2.6M | -$10.0M | -$12.9M | -$17.4M | -$11.3M | -$16.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 56.6% | -1135.8% | — | — | -27966.7% | -110481.3% | — | -11601.8% |
| Net margin | 61.6% | -1056.3% | — | — | -26872.9% | -107500.0% | — | -11478.1% |
Company news
May 22, 2026
May 15, 2026
May 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Xanthopoulos Kleanthis Gabriel | Award | 3,738 | $0.00 | $0.00 | filing |
| 2026-06-30 | LIU JEAN I | Award | 6,718 | $0.00 | $0.00 | filing |
| 2026-05-29 | Huang James | Buy | 150,000 | $2.48 | $371,610.00 | filing |
| 2026-03-31 | Huang James | Buy | 1,160,000 | $3.45 | $4.0M | filing |
| 2026-03-31 | Xanthopoulos Kleanthis Gabriel | Award | 2,816 | $0.00 | $0.00 | filing |
| 2026-03-31 | LIU JEAN I | Award | 5,061 | $0.00 | $0.00 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.